285 related articles for article (PubMed ID: 30859382)
1. Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function.
Ikonomidis I; Pavlidis G; Katsimbri P; Andreadou I; Triantafyllidi H; Tsoumani M; Varoudi M; Vlastos D; Makavos G; Kostelli G; Βenas D; Lekakis J; Parissis J; Boumpas D; Alexopoulos D; Iliodromitis E
Clin Res Cardiol; 2019 Oct; 108(10):1093-1101. PubMed ID: 30859382
[TBL] [Abstract][Full Text] [Related]
2. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis.
Ikonomidis I; Tzortzis S; Andreadou I; Paraskevaidis I; Katseli C; Katsimbri P; Pavlidis G; Parissis J; Kremastinos D; Anastasiou-Nana M; Lekakis J
Circ Cardiovasc Imaging; 2014 Jul; 7(4):619-28. PubMed ID: 24782115
[TBL] [Abstract][Full Text] [Related]
3. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis.
Ikonomidis I; Tzortzis S; Lekakis J; Paraskevaidis I; Andreadou I; Nikolaou M; Kaplanoglou T; Katsimbri P; Skarantavos G; Soucacos P; Kremastinos DT
Heart; 2009 Sep; 95(18):1502-7. PubMed ID: 19482847
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis.
Ikonomidis I; Lekakis JP; Nikolaou M; Paraskevaidis I; Andreadou I; Kaplanoglou T; Katsimbri P; Skarantavos G; Soucacos PN; Kremastinos DT
Circulation; 2008 May; 117(20):2662-9. PubMed ID: 18474811
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19.
Ikonomidis I; Pavlidis G; Katsimbri P; Lambadiari V; Parissis J; Andreadou I; Tsoumani M; Boumpas D; Kouretas D; Iliodromitis E
Food Chem Toxicol; 2020 Nov; 145():111694. PubMed ID: 32822775
[TBL] [Abstract][Full Text] [Related]
6. Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis.
Ikonomidis I; Papadavid E; Makavos G; Andreadou I; Varoudi M; Gravanis K; Theodoropoulos K; Pavlidis G; Triantafyllidi H; Moutsatsou P; Panagiotou C; Parissis J; Iliodromitis E; Lekakis J; Rigopoulos D
Circ Cardiovasc Imaging; 2017 Sep; 10(9):. PubMed ID: 28899951
[TBL] [Abstract][Full Text] [Related]
7. Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra.
Ikonomidis I; Tzortzis S; Lekakis J; Paraskevaidis I; Dasou P; Parissis J; Nikolaou M; Markantonis SL; Katsimbri P; Skarantavos G; Andreadou I; Anastasiou-Nana M
Thromb Haemost; 2011 Nov; 106(5):959-67. PubMed ID: 21947196
[TBL] [Abstract][Full Text] [Related]
8. Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis.
Makavos G; Ikonomidis I; Andreadou I; Varoudi M; Kapniari I; Loukeri E; Theodoropoulos K; Pavlidis G; Triantafyllidi H; Thymis J; Parissis J; Tsoumani M; Rafouli-Stergiou P; Katsimbri P; Papadavid E
Can J Cardiol; 2020 Jan; 36(1):100-111. PubMed ID: 31606265
[TBL] [Abstract][Full Text] [Related]
9. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
[TBL] [Abstract][Full Text] [Related]
10. Similarities in coronary function and myocardial deformation between psoriasis and coronary artery disease: the role of oxidative stress and inflammation.
Ikonomidis I; Makavos G; Papadavid E; Varoudi M; Andreadou I; Gravanis K; Theodoropoulos K; Pavlidis G; Triantafyllidi H; Parissis J; Paraskevaidis I; Rigopoulos D; Lekakis J
Can J Cardiol; 2015 Mar; 31(3):287-95. PubMed ID: 25660150
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study.
Bacchiega BC; Bacchiega AB; Usnayo MJ; Bedirian R; Singh G; Pinheiro GD
J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28288972
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
Van Tassell BW; Canada J; Carbone S; Trankle C; Buckley L; Oddi Erdle C; Abouzaki NA; Dixon D; Kadariya D; Christopher S; Schatz A; Regan J; Viscusi M; Del Buono M; Melchior R; Mankad P; Lu J; Sculthorpe R; Biondi-Zoccai G; Lesnefsky E; Arena R; Abbate A
Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29141858
[TBL] [Abstract][Full Text] [Related]
13. Optimal Blood Pressure Control Improves Left Ventricular Torsional Deformation and Vascular Function in Newly Diagnosed Hypertensives: a 3-Year Follow-up Study.
Tzortzis S; Ikonomidis I; Triantafyllidi H; Trivilou P; Pavlidis G; Katsanos S; Katogiannis K; Birba D; Thymis J; Makavos G; Varoudi M; Frogoudaki A; Vrettou AR; Vlastos D; Parissis J; Lekakis J
J Cardiovasc Transl Res; 2020 Oct; 13(5):814-825. PubMed ID: 31898757
[TBL] [Abstract][Full Text] [Related]
14. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction.
Holte E; Kleveland O; Ueland T; Kunszt G; Bratlie M; Broch K; Michelsen AE; Bendz B; Amundsen BH; Aakhus S; Damås JK; Gullestad L; Aukrust P; Wiseth R
Heart; 2017 Oct; 103(19):1521-1527. PubMed ID: 28432157
[TBL] [Abstract][Full Text] [Related]
15. Interplay Between Systemic Inflammation, Myocardial Injury, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis: Results From the LiiRA Study.
Weber B; Weisenfeld D; Massarotti E; Seyok T; Cremone G; Lam E; Golnik C; Brownmiller S; Liu F; Huang S; Todd DJ; Coblyn JS; Weinblatt ME; Cai T; Dahal K; Kohler M; Yinh J; Barrett L; Solomon DH; Plutzky J; Schelbert HR; Campisi R; Bolster MB; Di Carli M; Liao KP
J Am Heart Assoc; 2024 May; 13(9):e030387. PubMed ID: 38686879
[TBL] [Abstract][Full Text] [Related]
16. Pulse wave velocity to global longitudinal strain ratio in hypertension.
Ikonomidis I; Katsanos S; Triantafyllidi H; Parissis J; Tzortzis S; Pavlidis G; Trivilou P; Makavos G; Varoudi M; Frogoudaki A; Vrettou AR; Vlastos D; Lekakis J; Iliodromitis E
Eur J Clin Invest; 2019 Feb; 49(2):e13049. PubMed ID: 30422317
[TBL] [Abstract][Full Text] [Related]
17. The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis.
Marder W; Khalatbari S; Myles JD; Hench R; Lustig S; Yalavarthi S; Parameswaran A; Brook RD; Kaplan MJ
J Am Heart Assoc; 2013 Nov; 2(6):e000441. PubMed ID: 24252844
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
[TBL] [Abstract][Full Text] [Related]
19. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
Provan SA; Berg IJ; Hammer HB; Mathiessen A; Kvien TK; Semb AG
PLoS One; 2015; 10(6):e0130709. PubMed ID: 26114946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
